Invesco’s Crescent Biopharma CBIO Stock Holding History

Invesco’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$211K	Buy	+11,731	New	+$229K	﹤0.01%	3578
2021 Q1	–	Sell	-422	Closed	-$159K	–	3890
2020 Q4	$159K	Buy	422 +40	+10%	+$14K	﹤0.01%	3581
2020 Q3	$117K	Sell	382 -11	-3%	-$4.21K	﹤0.01%	3560
2020 Q2	$148K	Sell	393 -23,490	-98%	-$6.65M	﹤0.01%	3540
2020 Q1	$5.44M	Sell	23,883 -23,844	-50%	-$9.11M	﹤0.01%	1829
2019 Q4	$25.2M	Buy	47,727 +109	+0.2%	+$59K	0.01%	1290
2019 Q3	$20.5M	Sell	47,618 -47	-0.1%	-$30.2K	0.01%	1394
2019 Q2	$56.8M	Buy	+47,665	New	+$57M	0.01%	975
2018 Q2	–	Sell	-1,178	Closed	-$1.91M	–	3890
2018 Q1	$1.91M	Sell	1,178 -617	-34%	-$1.28M	﹤0.01%	2622
2017 Q4	$3.01M	Buy	+1,795	New	+$2.37M	﹤0.01%	2296
2016 Q4	–	Sell	-1,294	Closed	-$925K	–	3692
2016 Q3	$925K	Buy	1,294 +118	+10%	+$90.3K	﹤0.01%	2989
2016 Q2	$855K	Buy	+1,176	New	+$810K	﹤0.01%	2987

Other funds holding CBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco's CBIO Position: Q2 2026 in Review

Invesco opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 11,731 shares worth $211K. The stake represents ﹤0.01% of the portfolio and ranks #3578 among its holdings. This is a return to the name: Invesco previously reported a position in CBIO as recently as Q4 2020.

Invesco first reported a position in CBIO in Q2 2016 and has held it in 12 quarters since. The position peaked at $56.8M in Q2 2019. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

Invesco held 11,731 shares of Crescent Biopharma worth $211K as of Q2 2026.
Crescent Biopharma was a new Invesco position in Q2 2026.
Crescent Biopharma made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3578 holding.
Invesco first reported a position in Crescent Biopharma in Q2 2016 and has held it in 12 quarters since.
Invesco's Crescent Biopharma position peaked at $56.8M in Q2 2019.
82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.